FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012020910> ?p ?o ?g. }

• W2012020910 endingPage "8327" @default.
• W2012020910 startingPage "8319" @default.
• W2012020910 abstract "Activated vascular wall macrophages can rapidly internalize modified lipoproteins and escalate the growth of atherosclerotic plaques. This article proposes a biomaterials-based therapeutic intervention for depletion of non-regulated cholesterol accumulation and inhibition of inflammation of macrophages. Macromolecules with high scavenger receptor (SR)-binding activity were investigated for SR-mediated delivery of agonists to cholesterol-trafficking nuclear liver-X receptors. From a diverse feature space of a family of amphiphilic macromolecules of linear and aromatic mucic acid backbones modified with varied aliphatic chains and conjugated with differentially branched poly(ethylene glycol), a key molecule (carboxyl-terminated, C12-derivatized, linear mucic acid backbone) was selected for its ability to preferentially bind scavenger receptor A (SR-A) as the key target. At a basal level, this macromolecule suppressed the pro-inflammatory signaling of activated THP-1 macrophages while competitively lowering oxLDL uptake in vitro through scavenger receptor SRA-1 targeting. To further deplete intracellular cholesterol, the core macromolecule structure was exploited to solubilize a hydrophobic small molecule agonist for nuclear Liver-X Receptors, which regulate the efflux of intracellular cholesterol. The macromolecule-encapsulated agonist system was found to reduce oxLDL accumulation by 88% in vitro in comparison to controls. in vivo studies were designed to release the macromolecules (with or without encapsulated agonist) to injured carotid arteries within Sprague Dawley rats fed a high fat diet, conditions that yield enhanced cholesterol accumulation and macrophage recruitment. The macromolecules lowered intimal levels of accumulated cholesterol (50% for macromolecule alone; 70% for macromolecule-encapsulated agonist) and inhibited macrophage retention (92% for macromolecule; 96% for macromolecule-encapsulated agonist; 4 days) relative to non-treated controls. Thus, this study highlights the promise of designing bioactive macromolecule therapeutics based on scavenger receptor targeting, for potential management of vascular arterial disease." @default.
• W2012020910 created "2016-06-24" @default.
• W2012020910 creator A5001859759 @default.
• W2012020910 creator A5004498168 @default.
• W2012020910 creator A5008493337 @default.
• W2012020910 creator A5009304339 @default.
• W2012020910 creator A5012030142 @default.
• W2012020910 creator A5013693198 @default.
• W2012020910 creator A5021003355 @default.
• W2012020910 creator A5038860197 @default.
• W2012020910 creator A5042286700 @default.
• W2012020910 creator A5072142302 @default.
• W2012020910 creator A5082245391 @default.
• W2012020910 date "2011-11-01" @default.
• W2012020910 modified "2023-10-18" @default.
• W2012020910 title "Dual use of amphiphilic macromolecules as cholesterol efflux triggers and inhibitors of macrophage athero-inflammation" @default.
• W2012020910 cites W1515994079 @default.
• W2012020910 cites W1968631573 @default.
• W2012020910 cites W1975905715 @default.
• W2012020910 cites W1990964768 @default.
• W2012020910 cites W1992432184 @default.
• W2012020910 cites W2001382449 @default.
• W2012020910 cites W2018685928 @default.
• W2012020910 cites W2020153835 @default.
• W2012020910 cites W2022865224 @default.
• W2012020910 cites W2038428360 @default.
• W2012020910 cites W2043067840 @default.
• W2012020910 cites W2043725160 @default.
• W2012020910 cites W2049401036 @default.
• W2012020910 cites W2053663574 @default.
• W2012020910 cites W2060376234 @default.
• W2012020910 cites W2079404954 @default.
• W2012020910 cites W2087821055 @default.
• W2012020910 cites W2090769600 @default.
• W2012020910 cites W2092789730 @default.
• W2012020910 cites W2094901737 @default.
• W2012020910 cites W2094941678 @default.
• W2012020910 cites W2096096506 @default.
• W2012020910 cites W2102848212 @default.
• W2012020910 cites W2118198852 @default.
• W2012020910 cites W2129471397 @default.
• W2012020910 cites W2134040192 @default.
• W2012020910 cites W2134315288 @default.
• W2012020910 cites W2137467975 @default.
• W2012020910 cites W2140911607 @default.
• W2012020910 cites W2151426663 @default.
• W2012020910 cites W2153245546 @default.
• W2012020910 cites W2159332620 @default.
• W2012020910 cites W2165104851 @default.
• W2012020910 cites W2168000929 @default.
• W2012020910 cites W2182369053 @default.
• W2012020910 cites W2916392902 @default.
• W2012020910 cites W3196550503 @default.
• W2012020910 cites W4210363776 @default.
• W2012020910 cites W4233879183 @default.
• W2012020910 doi "https://doi.org/10.1016/j.biomaterials.2011.07.039" @default.
• W2012020910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3167147" @default.
• W2012020910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21816466" @default.
• W2012020910 hasPublicationYear "2011" @default.
• W2012020910 type Work @default.
• W2012020910 sameAs 2012020910 @default.
• W2012020910 citedByCount "24" @default.
• W2012020910 countsByYear W20120209102012 @default.
• W2012020910 countsByYear W20120209102013 @default.
• W2012020910 countsByYear W20120209102014 @default.
• W2012020910 countsByYear W20120209102015 @default.
• W2012020910 countsByYear W20120209102016 @default.
• W2012020910 countsByYear W20120209102018 @default.
• W2012020910 countsByYear W20120209102019 @default.
• W2012020910 countsByYear W20120209102020 @default.
• W2012020910 countsByYear W20120209102021 @default.
• W2012020910 countsByYear W20120209102022 @default.
• W2012020910 crossrefType "journal-article" @default.
• W2012020910 hasAuthorship W2012020910A5001859759 @default.
• W2012020910 hasAuthorship W2012020910A5004498168 @default.
• W2012020910 hasAuthorship W2012020910A5008493337 @default.
• W2012020910 hasAuthorship W2012020910A5009304339 @default.
• W2012020910 hasAuthorship W2012020910A5012030142 @default.
• W2012020910 hasAuthorship W2012020910A5013693198 @default.
• W2012020910 hasAuthorship W2012020910A5021003355 @default.
• W2012020910 hasAuthorship W2012020910A5038860197 @default.
• W2012020910 hasAuthorship W2012020910A5042286700 @default.
• W2012020910 hasAuthorship W2012020910A5072142302 @default.
• W2012020910 hasAuthorship W2012020910A5082245391 @default.
• W2012020910 hasBestOaLocation W20120209102 @default.
• W2012020910 hasConcept C110459506 @default.
• W2012020910 hasConcept C12554922 @default.
• W2012020910 hasConcept C15920480 @default.
• W2012020910 hasConcept C170493617 @default.
• W2012020910 hasConcept C178790620 @default.
• W2012020910 hasConcept C185592680 @default.
• W2012020910 hasConcept C202751555 @default.
• W2012020910 hasConcept C204389451 @default.
• W2012020910 hasConcept C2778163477 @default.
• W2012020910 hasConcept C2778938600 @default.
• W2012020910 hasConcept C2779244956 @default.
• W2012020910 hasConcept C2780072125 @default.
• W2012020910 hasConcept C41443022 @default.

• next